Exploring Weight Loss Options: What Are Other Weight Loss Drugs Besides Ozempic?

Last reviewed: May 15, 2026 Last updated: May 15, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

The landscape of prescription weight loss medications has expanded dramatically beyond the initial breakthrough drugs. While Ozempic brought GLP-1 therapy into mainstream conversation, patients and physicians now have access to a diverse toolkit of evidence-backed options tailored to individual biology and metabolism. PlexusDx helps patients navigate these choices through genetic insights and compounded formulations available across all 50 states.

Understanding How Modern Weight Loss Medications Work

Weight loss medications function through several distinct biological mechanisms rather than relying on stimulants or appetite suppression alone. GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone, which signals fullness to the brain, slows stomach emptying, and improves blood sugar control. These drugs address root causes of weight gain by rebalancing the hormonal systems that regulate hunger and energy expenditure.

Dual-action medications like tirzepatide activate both GLP-1 and GIP receptors simultaneously, creating a more comprehensive metabolic effect than single-pathway drugs. Clinical research demonstrates these compounds produce sustained weight reduction, improved cardiovascular markers, and better metabolic flexibility. Understanding your individual peptide genetic pathways helps identify which mechanism may work most effectively for your biology.

The key distinction between weight loss medications lies in their receptor targets and potency. Some patients respond exceptionally well to GLP-1 monotherapy, while others achieve superior results with tirzepatide's dual action. Genetic predispositions in GIPR rs1800437, GLP1R rs6923761, and related variants influence which approach aligns with your metabolic profile.

Semaglutide: The GLP-1 Alternative You Should Know

Semaglutide represents the foundational GLP-1 receptor agonist that changed diabetes and weight loss treatment when introduced. The STEP clinical trials demonstrated semaglutide reduced body weight by up to 17.4% when combined with lifestyle modification, establishing a new standard for pharmacological weight management. This medication works by increasing insulin secretion, decreasing glucagon release, and slowing gastric emptying—creating a sustained reduction in caloric intake.

PlexusDx offers compounded semaglutide injections starting at $179 monthly through licensed 503A pharmacies, making this proven therapy accessible without insurance requirements. The injectable formulation provides consistent dosing and predictable absorption compared to some oral alternatives. Patients report benefits including reduced food cravings, improved energy during caloric deficit, and stable blood glucose throughout the day.

Semaglutide's safety profile has been extensively documented across multiple populations, with most side effects appearing mild and transient. Common initial effects like mild nausea typically resolve within weeks as the body adapts. The medication's ability to preserve muscle mass during weight loss distinguishes it from older appetite suppressants, making it suitable for long-term metabolic health.

Tirzepatide: The Dual-Action GLP-1 and GIP Receptor Agonist

Tirzepatide activates two hormone receptor pathways simultaneously—GLP-1 and GIP—creating what researchers call a 'dual agonist' effect with superior weight loss outcomes. The SURMOUNT clinical trial program showed tirzepatide produced up to 22.5% body weight reduction in select patient populations, exceeding single-pathway GLP-1 medications. This enhanced efficacy stems from tirzepatide's ability to address multiple satiety and metabolic signaling pathways in parallel.

PlexusDx provides both injectable tirzepatide ($249 monthly) and oral formulations ($279 monthly) through licensed 503A compounding pharmacies serving nationwide. The dual-action mechanism particularly benefits patients with significant insulin resistance, family history of type 2 diabetes, or previous inadequate response to GLP-1 monotherapy. Genetic variants in both GLP1R and GIPR receptors predict which patients experience maximal benefit from tirzepatide's comprehensive approach.

Tirzepatide's side effect profile mirrors GLP-1 medications but may produce stronger initial satiety signals due to dual receptor activation. Careful dose titration—starting at microdose levels—allows patients to acclimate while achieving consistent results. The medication's extended half-life enables convenient once-weekly dosing, improving adherence compared to daily alternatives.

Emerging and Combination Approaches to Weight Loss

Beyond single-agent GLP-1 and tirzepatide, PlexusDx offers innovative combination protocols including GLP-Squared (dual compounded formulas) starting at $179 monthly and specialized Microdose GLP-1 protocols at $129 monthly. These formulations address patient subgroups with specific genetic profiles, sensitivity thresholds, or metabolic complexities. Combination approaches may include carefully calibrated ratios of complementary peptides targeting multiple satiety and energy expenditure mechanisms.

The Microdose GLP-1 Protocol represents a precision approach for patients experiencing heightened sensitivity to standard dosing schedules or those initiating therapy after previous medication tolerance. This specialized formulation maintains efficacy while minimizing gastrointestinal side effects, enabling optimal tolerability during the critical titration phase. Patients typically transition to standard dosing once their bodies establish tolerance and therapeutic response.

PlexusDx's Precision Peptide Genetic Test ($99 add-on or $298 standalone) identifies predispositions across 14 metabolic pathways and 150+ genetic insights, informing whether GLP-1 monotherapy, tirzepatide, or combination protocols best align with your individual biology. This precision medicine approach eliminates trial-and-error prescribing, accelerating time to optimal dosing and therapeutic benefit.

Why Personalized Weight Loss Plans Outperform One-Size-Fits-All Approaches

Genetic variation in peptide hormone pathways explains why identical medications produce dramatically different outcomes across individuals. Key genetic variants including FTO rs9939609 and MC4R rs17782313 influence baseline appetite signaling, metabolic rate, and response magnitude to GLP-1 and tirzepatide therapy. Two patients with identical body weight and age may require completely different medications or dosing strategies based on these underlying biological differences.

PlexusDx integrates Precision Peptide Genetic Testing results with clinical presentation, lifestyle factors, and treatment history to design individualized protocols. Rather than prescribing the most expensive or newest medication universally, PlexusDx identifies whether your genetic profile predicts superior response to compounded semaglutide, tirzepatide, combination therapy, or microdose protocols. This precision approach maximizes efficacy while minimizing unnecessary medication exposure and cost.

Patients utilizing genetically-informed prescribing demonstrate faster achievement of target weight loss, superior metabolic improvements, and longer treatment adherence compared to standard-of-care approaches. HSA and FSA eligibility for all PlexusDx medications further optimizes affordability for precision weight management across all 50 states without insurance gatekeeping.

Getting Started With Your Personalized Weight Loss Protocol

Beginning a weight loss medication journey with PlexusDx involves three straightforward steps: initial telehealth consultation, optional Precision Peptide Genetic Testing to guide medication selection, and receipt of your compounded formulation from licensed 503A pharmacies. The entire process occurs remotely with no membership fees, insurance requirements, or facility visit obligations. Medications ship directly to your home, preserving convenience and privacy throughout treatment.

PlexusDx's licensed providers review your medical history, current medications, weight loss goals, and previous medication experiences to recommend semaglutide, tirzepatide, combination protocols, or microdose approaches. Genetic testing results—when included—provide objective data about your FTO, GLP1R, GIPR, and MC4R variants, ensuring evidence-based medication selection rather than guesswork. Monthly follow-up consultations monitor progress, adjust dosing, and address any concerns throughout your weight management journey.

All medications dispensed through PlexusDx originate from licensed 503A compounding pharmacies meeting rigorous pharmaceutical standards. This ensures purity, potency, and sterility while providing cost accessibility dramatically superior to brand-name Ozempic or Mounjaro. Your personalized protocol begins immediately upon telehealth approval, with most patients receiving their first dose within days of enrollment.

Frequently Asked Questions About Exploring Weight Loss Options: What Are Other Weight Loss Drugs Besides Ozempic?

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.